AMGN Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
10.1B
+16.7%
8.6B
-12.6%
9.9B
+3.2%
9.6B
+4.1%
9.2B
Cost of Revenue
2.8B
+2.4%
2.7B
-7.8%
3.0B
-3.4%
3.1B
+2.4%
3.0B
Gross Profit
7.2B
+23.3%
5.9B
-14.7%
6.9B
+6.4%
6.5B
+5.0%
6.2B
Operating Expenses
3.7B
+16.2%
3.2B
-23.1%
4.2B
+5.6%
3.9B
+12.4%
3.5B
R&D
1.9B
+8.7%
1.7B
-19.7%
2.1B
+12.7%
1.9B
+8.9%
1.7B
SG&A
1.7B
+8.9%
1.6B
-17.9%
2.0B
+13.5%
1.7B
+1.7%
1.7B
Operating Income
3.5B
+31.8%
2.7B
-2.0%
2.7B
+7.7%
2.5B
-4.9%
2.7B
EBITDA
4.6B
+22.3%
3.8B
-1.8%
3.9B
+0.5%
3.8B
-4.1%
4.0B
Net Income
2.4B
+30.6%
1.8B
+36.5%
1.3B
-58.6%
3.2B
+124.6%
1.4B
EPS (Basic)
$4.40
+30.6%
$3.37
+35.9%
$2.48
-58.5%
$5.98
+124.8%
$2.66
EPS (Diluted)
$4.37
+30.8%
$3.34
+36.3%
$2.45
-58.7%
$5.93
+123.8%
$2.65
Shares (Diluted)
544.0M
+0.0%
544.0M
+0.0%
544.0M
+0.4%
542.0M
+0.2%
541.0M
Amgen (AMGN) โ€” Financials